Alexander Kamb Selected Research

2- hydroxy- 1- (2- ((9- (4- methylcyclohexyl)- 9H- pyrido(4',3'- 4,5)pyrrolo(2,3- d)pyrimidin- 2- yl)amino)- 7,8- dihydro- 1,6- naphthyridin- 6(5H)- yl)ethanone

2/2015	AMG 925 is a dual FLT3/CDK4 inhibitor with the potential to overcome FLT3 inhibitor resistance in acute myeloid leukemia.
4/2014	Preclinical evaluation of AMG 925, a FLT3/CDK4 dual kinase inhibitor for treating acute myeloid leukemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alexander Kamb Research Topics

Disease

18	Neoplasms (Cancer) 12/2022 - 06/2003
2	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 11/2003
2	Melanoma (Melanoma, Malignant) 01/2020 - 03/2003
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 02/2015 - 04/2014
1	Colitis 01/2022
1	Inflammation (Inflammations) 01/2022
1	Lung Neoplasms (Lung Cancer) 01/2022
1	Lymphoma (Lymphomas) 01/2020
1	Body Weight (Weight, Body) 04/2014
1	Prostatic Hyperplasia (Benign Prostatic Hyperplasia) 09/2010
1	Prostatic Diseases 09/2010
1	Carcinoma (Carcinomatosis) 09/2010

Drug/Important Bio-Agent (IBA)

4	AntigensIBA 12/2022 - 01/2021
2	HLA-A Antigens (HLA-A)IBA 01/2022 - 12/2020
2	Chimeric Antigen ReceptorsIBA 01/2022 - 01/2020
2	2- hydroxy- 1- (2- ((9- (4- methylcyclohexyl)- 9H- pyrido(4',3'- 4,5)pyrrolo(2,3- d)pyrimidin- 2- yl)amino)- 7,8- dihydro- 1,6- naphthyridin- 6(5H)- yl)ethanoneIBA 02/2015 - 04/2014
1	Carcinoembryonic AntigenIBA 01/2022
1	SolutionsIBA 01/2022
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2022
1	MesothelinIBA 01/2022
1	Surface Antigens (Surface Antigen)IBA 12/2020
1	AntibodiesIBA 01/2020
1	Phosphotransferases (Kinase)IBA 04/2014
1	sphingosine kinaseIBA 01/2013
1	Indicators and Reagents (Reagents)IBA 01/2013
1	ChromatinIBA 05/2009
1	Cadherins (E-Cadherin)IBA 11/2003
1	beta CateninIBA 11/2003
1	Peptides (Polypeptides)IBA 06/2003
1	Proteins (Proteins, Gene)FDA Link 06/2003
1	RetinoidsIBA 03/2003

Therapy/Procedure

11	Therapeutics 12/2022 - 08/2010
3	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2022 - 01/2022
1	Immunotherapy 01/2022